Music-based walking therapy for NMOSD
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a music-based walking therapy (called MR-C-014) to see if it is safe and well-tolerated for people with NMOSD who have trouble walking. It may help improve your walking pattern and strength.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with neuromyelitis optica spectrum disorder (NMOSD) and have had a past episode of transverse myelitis (inflammation of the spinal cord).
- You have a walking problem because of NMOSD, and you can walk at a slow to moderate pace (with or without a cane, walker, or brace).
- You can walk for up to 30 minutes safely (with breaks if needed, but not sitting down during the walking test).
- You have not had a relapse or hospitalization for NMOSD in the last 3 months, and you haven't changed your disease-modifying therapy in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
This trial tests a structured wellness program to improve quality of life for people with neuromyelitis optica (NMOSD). It is designed to be accessible for any level of disability.
This study tests whether walking to a steady beat of music can help improve your walking and balance. It is for people with mild to moderate multiple sclerosis who can walk but may need a little support.
This study tests a digital music-based walking program that creates personalized playlists to help improve how you walk and make it feel more automatic. It may be helpful if you can walk for at least 10 minutes without help and are in early to middle stages of Parkinson's disease.
This study tests a digital (phone) tool that helps people with NMOSD do unsupervised self-assessments between clinic visits. It looks at how well the tool works and whether it is safe and understandable for patients.
This study tests whether a new stem cell treatment (CE211NS21) is safe and well-tolerated in patients who have had a recent serious attack from NMOSD, a rare neurological condition. The treatment aims to reduce disability and vision loss from this disease.
Hear when a new Neuromyelitis Optica Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.